Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Gilead Hep-C pipeline drug hits speed bump: relapse in genotype 1 null responders

This article was originally published in Scrip

Executive Summary

Shares of Gilead Sciences took a dive after the company announced that in the genotype 1 null responder cohort of the ongoing Phase II ELECTRON study, certain patients relapsed within four weeks of completing 12 weeks on a two-drug regimen of Gilead's experimental hepatitis C drug GS-7977, a nucleoside analogue, plus ribavirin.


Related Companies